Dr. Jairath oversees the global Medical R&D initiatives and services. In conjunction with the executive team and senior medical advisors, he assumes overall responsibility for research strategy, as well as performance of the organization’s Medical R&D services including medical operations, medical imaging, precision medicine, medical writing, medical monitoring, medical/biostatistics advisory collaborations and IBD fellowships. He also provides medical oversight for the design of clinical trials, protocol development and imaging R&D endpoints. Dr. Jairath was previously Director of Academic Research and Development (2016-19).
Dr. Jairath obtained his BSc (Pharmacology) and Medical Degree from the University of Leeds (UK), DPhil (PhD) in Clinical Medicine from the University of Oxford and post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine. He is Professor of Medicine at the Schulich School of Medicine and Dentistry, and holder of the John and Susan McDonald Endowed Chair in Inflammatory Bowel Disease (IBD) at Western University.
His specialist clinical training in Gastroenterology was completed in London and Oxford, and he holds specialist certification in both Ontario and the UK. Prior to moving to Western in 2016, he was a National Institute for Health Research Clinical Trials Fellow at the Oxford Clinical Trials Research Unit and Consultant Gastroenterologist at Oxford University Hospitals.
He is a practising gastroenterologist and specialist in IBD, and his research interests in clinical therapeutics for IBD include design of clinical trials, development and validation of outcome measures for use in clinical trials, patient reported outcome measures and prediction modelling for response to therapy.
Dr. Jairath has driven the development and validation of several novel indices for use in IBD clinical trials, like the UC-100 and the novel patient reported outcome measures, Symptom and Impacts Questionnaire for Ulcerative Colitis and Symptom and Impacts Questionnaire for Crohn’s Disease. In addition, he was instrumental to the delivery of the REACT2 trial and to the design of the VERDICT trial, both of which are important clinical practice questions for patients with Crohn’s disease and ulcerative colitis, respectively.
“We are what we repeatedly do. Excellence, then, is not an act, but a habit.” — Aristotle